The latest news on next-generation sequencing.
Revenues from product and product-related services more than doubled to $4.4 million, but collaborative development revenues sank 52 percent to $1.4 million.
The regulatory approval means that the assay for minimal residual disease is available to monitor B cell blood cancers in patients in all 50 states.
The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.
Blue Cross Blue Shield of Michigan's members will able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
For the three months ended June 30, the genomic testing firm reported total revenues of $30.1 million.
Qiagen's Q2 revenues of $381.6 million represented 5 percent year-over-year growth at constant exchange rates, but came in just under the Wall Street estimate.
During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.
Much of the growth was driven by contributions from Genoptix, which NeoGenomics acquired in late 2018. Organically, revenues were up 20 percent.
Blue Shield of California's members will be able to access Interpace's tests on an in-network basis, which will limit their out-of-pocket expenses.
Qiagen reported year-over-year net sales of 1 percent, or 5 percent at constant exchange rates ahead of its planned Q2 earnings release next week.